Time-Limited Initial Therapy for Young, Fit Patients with CLL
Mené sur 926 patients atteints d'une leucémie lymphoïde chronique, cet essai randomisé de phase III compare l'efficacité, du point de vue de la présence d'une maladie résiduelle au 15ème mois de traitement et de la survie sans progression, de 4 stratégies thérapeutiques de première ligne combinant vénétoclax et autres agents
First-line treatment for chronic lymphocytic leukemia (CLL) has changed dramatically over the past decade. The introduction of the covalent Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which has been shown to be superior to chemotherapy or chemoimmunotherapy with respect to progression-free survival, has been transformative.1-3 Subsequently, two second-generation BTK inhibitors (acalabrutinib and zanubrutinib) have been shown to have efficacy that is at least similar to that of ibrutinib, with better safety. In parallel, the B-cell lymphoma 2 (BCL2) antagonist venetoclax has been shown to have considerable efficacy in relapsed CLL. In a phase 3 trial, untreated patients with CLL and coexisting (...)
New England Journal of Medicine , éditorial, 2022